Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $69.50 -1.74%
Revenue Growth %: +22.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +22.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $13.71 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- H.C. Wainwright Reiterates Buy Rating on Anixa Biosciences (ANIX)
- Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
